慢性肾脏病患者COVID-19发病率与结局:系统综述与Meta分析
该系统综述与Meta分析检索MEDLINE、EMBASE和PubMed至2021年2月,纳入348项队列或病例对照研究,评估慢性肾脏病人群中COVID-19的发病率与结局。基于低确定性证据,接受透析的慢性肾脏病患者COVID-19发病率可能高于未接受肾脏替代治疗者或移植受者;合并COVID-19的慢性肾脏病患者死亡发生率可能高于未合并COVID-19者。
要点
- 透析患者COVID-19发病率可能高于非透析CKD患者及移植受者。
- CKD合并COVID-19者死亡发生率可能高于未合并COVID-19的CKD患者。
- 证据确定性普遍较低,多数研究未校正潜在混杂因素。
核心结论
- 接受维持性透析的慢性肾脏病患者COVID-19发病率可能高于未接受肾脏替代治疗者或肾脏/胰腺-肾脏移植受者。
- 合并COVID-19的慢性肾脏病患者死亡发生率可能高于未合并COVID-19的慢性肾脏病患者。
研究设计与样本
- 系统综述与Meta分析,检索MEDLINE、EMBASE和PubMed至2021年2月,纳入队列和病例对照研究。
- 共纳入348项研究,其中COVID-19合并CKD参与者382407例,CKD总参与者1139979例。
主要发现
- 透析治疗CKD患者COVID-19发病率为每10000人周105例(95%CI 91-120;95%PrI 25-235;59项研究;468233例参与者)。
- 未接受肾脏替代治疗的CKD患者COVID-19发病率为每10000人周16例(95%CI 4-33;95%PrI 0-92;5项研究;70683例参与者)。
- 肾脏或胰腺/肾脏移植受者COVID-19发病率为每10000人周23例(95%CI 18-30;95%PrI 2-67;29项研究;120281例参与者)。
- CKD合并COVID-19患者死亡发生率为每1000人周32例(95%CI 30-35;95%PrI 4-81;229项研究;70922例参与者)。
- 合并COVID-19的CKD患者死亡发生率可能高于未合并COVID-19者,发生率比为10.26(95%CI 6.78-15.53;95%PrI 2.62-40.15;4项研究;18347例参与者)。
临床怎么用
- 对透析患者应重视COVID-19的防控与监测,因其发病率可能较高。
- CKD患者合并COVID-19时需关注死亡风险升高,加强临床管理。
局限性
- 分析一般基于低确定性证据。
- 少数研究报告了未合并COVID-19的CKD患者结局,难以计算COVID-19归因的超额风险。
- 多数研究未校正潜在混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Coronavirus disease 2019 (COVID-19) disproportionately affects people with chronic diseases such as chronic kidney disease (CKD). We assessed the incidence and outcomes of COVID-19 in people with CKD. STUDY DESIGN: Systematic review and meta-analysis by searching MEDLINE, EMBASE, and PubMed through February 2021. SETTING & STUDY POPULATIONS: People with CKD with or without COVID-19. SELECTION CRITERIA FOR STUDIES: Cohort and case-control studies. DATA EXTRACTION: Incidences of COVID-19, death, respiratory failure, dyspnea, recovery, intensive care admission, hospital admission, need for supplemental oxygen, hospital discharge, sepsis, short-term dialysis, acute kidney injury, and fatigue. ANALYTICAL APPROACH: Random-effects meta-analysis and evidence certainty adjudicated using an adapted version of GRADE (Grading of Recommendations Assessment, Development and Evaluation). RESULTS: 348 studies (382,407 participants with COVID-19 and CKD; 1,139,979 total participants with CKD) were included. Based on low-certainty evidence, the incidence of COVID-19 was higher in people with CKD treated with dialysis (105 per 10,000 person-weeks; 95% CI, 91-120; 95% prediction interval [PrI], 25-235; 59 studies; 468,233 participants) than in those with CKD not requiring kidney replacement therapy (16 per 10,000 person-weeks; 95% CI, 4-33; 95% PrI, 0-92; 5 studies; 70,683 participants) or in kidney or pancreas/kidney transplant recipients (23 per 10,000 person-weeks; 95% CI, 18-30; 95% PrI, 2-67; 29 studies; 120,281 participants). Based on low-certainty evidence, the incidence of death in people with CKD and COVID-19 was 32 per 1,000 person-weeks (95% CI, 30-35; 95% PrI, 4-81; 229 studies; 70,922 participants), which may be higher than in people with CKD without COVID-19 (incidence rate ratio, 10.26; 95% CI, 6.78-15.53; 95% PrI, 2.62-40.15; 4 studies; 18,347 participants). LIMITATIONS: Analyses were generally based on low-certainty evidence. Few studies reported outcomes in people with CKD without COVID-19 to calculate the excess risk attributable to COVID-19, and potential confounders were not adjusted for in most studies. CONCLUSIONS: The incidence of COVID-19 may be higher in people receiving maintenance dialysis than in those with CKD not requiring kidney replacement therapy or those who are kidney or pancreas/kidney transplant recipients. People with CKD and COVID-19 may have a higher incidence of death than people with CKD without COVID-19.
引用
- Chung EYM, Palmer SC, Natale P, et al. Incidence and Outcomes of COVID-19 in People With CKD: A Systematic Review and Meta-analysis. Am J Kidney Dis. 2021. PMID: 34364906. doi:10.1053/j.ajkd.2021.07.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。